Methylphenidate
Methylphenidate Hydrochloride
Also known as: Concerta · Metadate · Methylin · Daytrana · Focalin · Equasym · Attenta · Rilatine · Riphenidate · Ritalina · Ritaline · Ritaphen · Rubifen · Tranquilyn
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Dosing by species
🌎 NA — North America🌍 EU — Europe
Dogs
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Treatment of narcolepsy/cataplexy | 5-10 mg (total dose) | PO | once daily | — | 🌎 NA |
| Treatment of narcolepsy/cataplexy (to supplement imipramine) | 0.25-0.5 mg/kg or 5-10 mg (total dose) | PO | q12-24h | — | 🌎 NA |
| Diagnosis and treatment of hyperkinesis | 5-20 mg (total dose) | PO | q8-12h | 3 days | 🌎 NA |
| Hyperkinesis-hyperactivity | Small dogs: 5+ mg total dose; Large Dogs: 20-40 mg total dose | PO | q12h | — | 🌎 NA |
- Treatment of narcolepsy/cataplexy (to supplement imipramine): Used to supplement imipramine given at 0.5-1 mg/kg PO q8-12h
- Diagnosis and treatment of hyperkinesis: Give for 3 days and assess for improvement of target behaviors (anxiety, overactivity, learning ability)
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
Methylphenidate is a central nervous system (CNS) stimulant that is structurally and pharmacologically related to amphetamines. In veterinary medicine, it is primarily utilized off-label for the diagnosis and management of narcolepsy/cataplexy and hyperkinesis (hyperactivity) in dogs.
Beyond its CNS effects, it possesses weak sympathomimetic activity but generally has minimal impact on peripheral circulation at standard therapeutic doses.
Clinical Pearl: Because methylphenidate is a Schedule II (C-II) controlled substance in the USA, it carries strict prescribing regulations and a significant risk for human diversion and abuse. Veterinarians must exercise appropriate legal and ethical precautions when dispensing.
Mechanism of action
Methylphenidate acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI).
- It binds to and blocks the dopamine transporter (DAT) and norepinephrine transporter (NET) on presynaptic neurons.
- Blockade of these transporters → prevents the reuptake of monoamines → increases the concentration of dopamine and norepinephrine in the extraneuronal space (synaptic cleft).
- This amplified monoamine signaling in the brainstem arousal system and cerebral cortex leads to increased alertness, focus, and CNS stimulation.
Safety & warnings
Contraindications
- Seizure disorders
- Cardiac disease or hypertension
- Aggressive animals
Adverse effects
- Tachycardia (increased heart rate)
- Tachypnea (increased respiratory rate)
- Anorexia
- Tremors
- Hyperthermia (particularly exercise-induced)
Precautions
Use with extreme caution in dogs with pre-existing seizure disorders, cardiac disease, hypertension, or those exhibiting aggressive behavior. Methylphenidate is a Class-II controlled substance with a high potential for human abuse; prescribe and dispense with strict adherence to controlled substance regulations.
Drug interactions
Methylphenidate may increase serum levels of these anticonvulsants
Rare cases of cardiovascular effects (including death) reported in humans; mechanism unknown
Methylphenidate may reduce the efficacy of hypotensive effects
Concurrent use could lead to a severe hypertensive crisis
Methylphenidate may inhibit SSRI metabolism and increase their serum levels
Methylphenidate may inhibit TCA metabolism and increase their serum levels
Methylphenidate may inhibit warfarin metabolism and increase INR
Monitoring
- Clinical efficacy (improvement in target behaviors or narcoleptic episodes)
- Vital signs (heart rate, respiratory rate)
- Body weight (monitor for anorexia/weight loss)
- Periodic CBC with differential and platelet counts (recommended during prolonged therapy based on human guidelines)
Pharmacokinetics
Half-life
Absorption
Dogs: Immediate-release tablets peak in ~15 minutes. Sustained-release tablets peak in ~30 minutes but with much lower peak concentrations. Humans: Rapidly and well absorbed from the GI tract; food may increase the rate but not the extent of absorption. Peak levels occur ~2 hours post-dose.
Distribution
Humans: Protein binding is low.
Metabolism
Humans: Extensively metabolized during the first-pass effect.
Elimination
Humans: Less than 1% is excreted unchanged in the urine. Clearance in dogs is rapid (0.27 L/hr for IR, 0.97 L/hr for SR).
Overdose
Toxicity can occur at relatively low doses in veterinary patients.
- Dogs: Doses of 1 mg/kg (or below) can cause toxic reactions. One fatality was reported at 3.1 mg/kg, though research dogs have survived 20 mg/kg/day for 90 days.
- Cats: A 5 mg tablet caused severe toxicity (tremors, agitation, mydriasis, tachycardia, tachypnea, hypertension) which resolved after 25 hours with supportive care.
Clinical Signs of Overdose: Primarily CNS over-stimulation and excessive sympathomimetic effects: hyperactivity, salivation, diarrhea, head bobbing, agitation, tachycardia, hypertension, tremors, seizures, and hyperthermia.
Treatment:
- Decontamination: Standard gut detoxification (emesis, activated charcoal, cathartic). Avoid emesis if the animal is already symptomatic due to seizure/aspiration risks.
- Supportive Care:
- Phenothiazines (e.g., acepromazine, chlorpromazine) to control agitation.
- Beta-blockers to manage severe tachycardia.
- External cooling for hyperthermia.
- Cyproheptadine may be administered to help prevent or treat serotonin syndrome.
Available products
Formulations
- Oral tablets
- Chewable tablets
- Extended-release tablets
- Extended-release capsules
- Oral solution
- Transdermal patch
Human-labeled
- Methylphenidate Oral Tablets: 5 mg, 10 mg & 20 mg
- Chewable Tablets: 2.5 mg, 5 mg & 10 mg
- Extended-Release Tablets: 10 mg, 18 mg, 20 mg, 27 mg, 36 mg & 54 mg
- Extended-Release Capsules: 20 mg, 30 mg, 40 mg, 50 mg & 60 mg
- Methylphenidate Oral Solution: 5 mg/5 mL & 10 mg/5 mL
- Methylphenidate Transdermal Patch: 10 mg/9 h, 15 mg/9 h, 20 mg/9 h & 30 mg/9 h
Regulatory status
No regulatory data for: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Unless otherwise noted on the label, methylphenidate tablets and extended-release tablets/capsules should be stored in tight, light-resistant containers at room temperature.
Client information
- Secure Storage: This medication is a controlled substance with a high potential for human abuse. Keep it stored securely in a locked cabinet or safe location.
- Administration: If your pet is prescribed an extended-release tablet or capsule, do not crush or chew it; it must be given whole.
- Monitoring: Watch your pet closely for signs of overstimulation, such as a racing heart, rapid breathing, restlessness, tremors, or loss of appetite. Report any of these signs to your veterinarian immediately.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.